| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| MISSLING CHRISTOPHER U | President and CEO, Director | 650 5TH AVENUE, 20TH FLOOR, NEW YORK | /s/Christopher Missling | 09 Jan 2026 | 0001196573 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AVXL | Stock Option (Right to Buy) | Award | $0 | +125,000 | $0.000000 | 125,000 | 06 Jan 2026 | Common Stock | 125,000 | $8.58 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a Second Regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares. |